October 21, 2017 10:30 AM ET

Healthcare Equipment and Supplies

Company Overview of Entellus Medical, Inc.

Company Overview

Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic and recurrent sinusitis. The company offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red trans-illumination of the sinus cavity with its battery power; Light Fiber, a single-use ...

3600 Holly Lane North

Suite 40

Plymouth, MN 55447

United States

Founded in 2006

280 Employees

Phone:

763-463-1595

Key Executives for Entellus Medical, Inc.

CEO, President & Director
Age: 55
Total Annual Compensation: $468.0K
CFO & Corporate Secretary
Age: 50
Total Annual Compensation: $183.3K
Compensation as of Fiscal Year 2016.

Entellus Medical, Inc. Key Developments

Entellus Medical, Inc. Presents at Dougherty and Company Institutional Investor Conference, Sep-19-2017

Entellus Medical, Inc. Presents at Dougherty and Company Institutional Investor Conference, Sep-19-2017 . Venue: Millennium Hotel, 1313 Nicollet Mall, Minneapolis, Minnesota, United States.

Entellus Medical, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017; Provides Earnings Guidance for the Third Quarter and Full Year of 2017

Entellus Medical, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2017. For the quarter, revenue was $22,140,000 compared with $18,730,000 a year ago. Net loss was $8,043,000 or $0.37 per basic and diluted share, compared with $5,021,000 or $0.27 per basic and diluted share, for the same period of the prior year. Loss from operations was $7,640,000 against $4,526,000 a year ago. The growth in revenue was attributable to increased sales of the company’s disposable products, including the XprESS family of products, as well as strong sales of capital products. Loss before income tax expense was $8,040,000 against $5,021,000 a year ago. Foreign currency exchange rates negatively impacted revenue by approximately $0.1 million for the quarter. For the six months, the company reported revenue of $41,246,000 against $35,632,000 a year ago. Loss from operations was $15,471,000 against $10,892,000 a year ago. Net loss was $16,381,000 against $11,893,000 a year ago. Net loss per basic and diluted share was $0.77 against $0.63 a year ago. Loss before income tax expense was $16,375,000 against $11,893,000 a year ago. The company expects third quarter 2017 revenue, inclusive of anticipated Spirox revenue, to be in a range of $22.8 million to $23.8 million, representing growth of 27% to 33% over third quarter 2016 revenue. Excluding the impact of purchase accounting, non-GAAP adjusted combined gross margin is expected to be in a range of 72% to 74% for the third quarter of 2017. Third quarter 2017 non-GAAP adjusted EBITDA, inclusive of Spirox operations, is expected to be in a range of negative $9.0 million to negative $11.0 million. The company expects full year 2017 revenue, inclusive of anticipated Spirox revenue from July 13 through year end, to be in a range of $91.5 million to $94.5 million, representing growth of 22% to 26% over 2016 revenue. Excluding the impact of purchase accounting, non-GAAP adjusted combined gross margin is expected to be in a range of 72% to 74% for the full year 2017. Full year 2017 non-GAAP adjusted EBITDA, inclusive of Spirox operations, is expected to be in a range of negative $22.0 million to negative $26.0 million. In light of its new adjusted EBITDA guidance, and to assist with the modeling, the company provided reconciliations from reported net loss to non-GAAP adjusted EBITDA for the previous 6 quarters on its website. Additionally, to provide the further context, based on its previously provided and now superseded full year stand-alone Entellus net loss guidance range of $24 million to $32 million, the corresponding adjusted EBITDA was expected to be in the range of negative $11 million to negative $19 million.

Entellus Medical, Inc. Presents at Canaccord Genuity 37th Annual Growth Conference, Aug-09-2017 08:30 AM

Entellus Medical, Inc. Presents at Canaccord Genuity 37th Annual Growth Conference, Aug-09-2017 08:30 AM. Venue: Intercontinental Hotel, 510 Atlantic Ave, Boston, Massachusetts, United States.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
July 7, 2017
Spirox, Inc.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
Bertelsmann AG Europe

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Entellus Medical, Inc., please visit www.entellusmedical.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.